南京药捷安康生物科技有限公司 Nanjing TransThera Biosciences Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies 2024-12-10 23:00
2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC) 2024-12-09 23:00
【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations 2024-04-12 21:00
TransThera Announced Global Phase 3 Clinical Trial for Cholangiocarcinoma Authorized in the European Union and Orphan Drug Designation for Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency 2024-03-08 21:00
TransThera initiates IND-Enabling studies for TT-02332, a novel, highly potent and CNS-penetrating NLRP3 inhibitor 2024-02-26 21:00
TransThera Announces the Global Multicenter Phase 3 Clinical Trial Completed First Patient Dosing in the US Evaluating Tinengotinib in FGFRi Relapsed/Refractory Patients with Cholangiocarcinoma 2023-12-21 21:45
2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer 2023-12-07 21:00
TransThera announces two oral presentations of tinengotinib clinical data at 2023 ESMO and SABCS annual meetings 2023-10-09 21:00
TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and Officially Accepted by the NMPA in China 2022-02-18 22:00
TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma 2021-11-03 22:00
TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China 2021-05-26 21:00
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration 2020-12-18 23:30
TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure 2019-12-17 08:00
TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma 2019-11-07 20:08
TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC 2018-09-28 20:00
1